<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03061474</url>
  </required_header>
  <id_info>
    <org_study_id>20163246</org_study_id>
    <nct_id>NCT03061474</nct_id>
  </id_info>
  <brief_title>Nicotinamide as an Early Alzheimer's Disease Treatment</brief_title>
  <acronym>NEAT</acronym>
  <official_title>A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to test whether nicotinamide, also known as vitamin B3
      or niacinamide, taken in high doses, can reduce phosphorylation of tau (the protein that
      accumulates in neurofibrillary tangles) in people with Mild Cognitive Impairment or mild
      Alzheimer's disease (AD) dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nicotinamide, the amide of nicotinic acid (vitamin B3/niacin), is an oral therapy with a
      wealth of clinical data in a variety of therapeutic areas, including preliminary data
      supporting its safety in Alzheimer's disease (AD). Preclinical work in a mouse model that
      develops both plaques and tangles supports the hypothesis that nicotinamide can act as a
      histone deacetylase (HDAC) inhibitor to reduce phosphorylation of tau.

      The study will implement a group sequential design, incorporating a futility analysis with a
      go/no-go decision conditional on cerebral spinal fluid CSF biomarker outcomes at 12-months.
      The primary outcome for the trial is change in p-tau231.

      This study timeline includes a screening phase of up to 60 days and treatment phase which is
      expected to last about 48 weeks and will include 4 study visits.

      An additional 12-month treatment and follow-up period is planned, contingent upon a &quot;go&quot;
      decision based on the primary outcome (CSF p-tau231) or one planned secondary outcome (CSF
      p-tau181)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind-Randomized</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in p-tau 231</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF phosphorylated tau (p-tau231) in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in p-tau 181</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF phosphorylated tau (p-tau181) in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total tau</measure>
    <time_frame>12 Months</time_frame>
    <description>Change in CSF total tau in individuals with mild Alzheimer's disease (AD) dementia or Mild Cognitive Impairment due to AD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Nicotinamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1500mg twice daily: 2, 750mg tablets taken orally twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1500mg twice daily: 2, 750mg tablets taken orally twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinamide</intervention_name>
    <description>Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.</description>
    <arm_group_label>Nicotinamide</arm_group_label>
    <other_name>Niacinamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease (AD)

          2. Biomarker criteria:

             Cerebral Spinal Fluid (CSF) Amyloid Beta 1-42 (Aβ42) &lt;= 600 pg/mL, or A ratio of total
             tau to Aβ42 ≥ 0.39.

          3. Mini-Mental State Exam (MMSE) ≥ 20

          4. Blood laboratories, urinalysis, and electrocardiogram are within normal limits or
             deemed clinically not significant by the site investigator

          5. Stable medications (including approved AD therapies) for at least 4 weeks

          6. At least 6 years of education

          7. Able to swallow oral tablets

          8. Speaks English fluently

          9. Available qualified study partner (≥3 times per week in-person communication with the
             participant)

        Exclusion Criteria:

          1. Active neurological or psychiatric diagnosis other than AD that may affect cognition
             and/or function. (Obstructive sleep apnea is permitted, if treated.)

          2. Inability to undergo lumbar puncture, including use of Coumadin, novel oral
             anticoagulants, clopidogrel, or dipyridamole. Use of aspirin &lt;= 325mg daily is
             permitted.

          3. Hachinski ischemic scale &gt; 4

          4. Magnetic Resonance Imaging (MRI) incompatibility

          5. MRI evidence of cortical stroke &gt;1cm, superficial siderosis, or extensive white matter
             hyperintensity (Cardiovascular Health Study score 7-8+)

          6. Diagnosis of cancer in the previous 5 years (with the exception of basal or squamous
             cell carcinoma)

          7. Geriatric Depression Scale (GDS) score &gt;6

          8. History within the past 5 years of alcohol or substance use disorder

          9. Laboratory evidence of a clinically significant abnormality that may interfere with
             study assessments

         10. Active partial or total malabsorptive disease (e.g., celiac disease)

         11. Resides in a skilled nursing facility

         12. Participation in a clinical trial of a potential disease-modifying therapy for AD in
             previous 6-months (time between last investigational drug administration and baseline
             for the current study)

         13. Pregnant, lactating or of child bearing potential (that is, women must be 2 years
             post-menopausal or surgically sterile to be considered not child bearing potential).

         14. Unwillingness to abstain from over-the-counter nicotinamide for the duration of the
             trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Grill, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Psychiatry and Human Behavior</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua Grill, Ph.D.</last_name>
    <phone>949-824-5905</phone>
    <email>jgrill@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Witbracht, Ph.D.</last_name>
    <phone>949-824-3249</phone>
    <email>mwitbrac@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Yanez, R.N</last_name>
      <phone>949-824-0008</phone>
      <email>byanez@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Huong Nguyen</last_name>
      <phone>949-824-0008</phone>
      <email>huongtn2@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Aimee Pierce, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celine Ossinalde, MA</last_name>
      <phone>310-794-6191</phone>
      <email>cossinalde@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Kremen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, LaFerla FM. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008 Nov 5;28(45):11500-10. doi: 10.1523/JNEUROSCI.3203-08.2008.</citation>
    <PMID>18987186</PMID>
  </reference>
  <reference>
    <citation>Liu D, Pitta M, Jiang H, Lee JH, Zhang G, Chen X, Kawamoto EM, Mattson MP. Nicotinamide forestalls pathology and cognitive decline in Alzheimer mice: evidence for improved neuronal bioenergetics and autophagy procession. Neurobiol Aging. 2013 Jun;34(6):1564-80. doi: 10.1016/j.neurobiolaging.2012.11.020. Epub 2012 Dec 25. Erratum in: Neurobiol Aging. 2013 Sep;34(9):e3.</citation>
    <PMID>23273573</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Joshua Grill</investigator_full_name>
    <investigator_title>Associate Professor, Psychiatry &amp; Human Behavior</investigator_title>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Nicotinamide</keyword>
  <keyword>Niacinamide</keyword>
  <keyword>Niacin</keyword>
  <keyword>Nicotinic Acids</keyword>
  <keyword>Vitamin</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Tauopathies</keyword>
  <keyword>Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

